Literature DB >> 11747452

Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide.

R Bucki1, P A Janmey, R Vegners, F Giraud, J C Sulpice.   

Abstract

During platelet activation, phosphatidylserine (PS) exposure on the extracellular face of the plasma membrane is associated with increased procoagulant activity. PS externalization is generally attributed to an increase in intracellular Ca(2+). Various phospholipid transporters, such as specific scramblases or proteins from the family of multidrug resistance proteins, and cofactors such as phosphatidylinositol 4,5-bisphosphate (PIP2) have been proposed to participate in this process. In this study, we used a membrane-permeant polycationic peptide (RhB-QRLFQVKGRR), derived from the PIP2-binding site of gelsolin (GS 160-169) and linked to rhodamine B, to investigate the role of PIP2 in PS externalization in whole platelets. The peptide penetrated rapidly into the platelets, specifically bound to PIP2, and induced PS exposure to a similar extent as thrombin or collagen, but independently of changes in intracellular Ca(2+) or phosphoinositide 3-kinase activity. A pretreatment of platelets with quercetin, an inhibitor of phosphoinositide metabolism, drastically decreased PS exposure induced by agonists or peptide. In large unilamellar vesicles (LUVs), the presence of PIP2 was strictly required for the induction of scrambling of NBD-labeled phospholipids (PC and PS) by the peptide. In inside-out vesicles from erythrocytes (IOVs), the peptide also induced redistribution of PC and PS. Our data suggest that, in intact platelets, PIP2 acts as a target of polycationic effectors, including Ca(2+), to promote PS exposure. The use of a membrane-permeant and fluorescent peptide which binds to PIP2 is a promising tool to investigate the role of PIP2 in various cellular processes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747452     DOI: 10.1021/bi010899c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

2.  Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes.

Authors:  Robert Bucki; Paul A Janmey
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.

Authors:  Crislyn D'Souza-Schorey; James W Clancy
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

4.  Involvement of the Na+/H+ exchanger in membrane phosphatidylserine exposure during human platelet activation.

Authors:  Robert Bucki; Jennifer J Pastore; Françoise Giraud; Paul A Janmey; Jean-Claude Sulpice
Journal:  Biochim Biophys Acta       Date:  2006-01-17

Review 5.  Counterion-mediated pattern formation in membranes containing anionic lipids.

Authors:  David R Slochower; Yu-Hsiu Wang; Richard W Tourdot; Ravi Radhakrishnan; Paul A Janmey
Journal:  Adv Colloid Interface Sci       Date:  2014-01-30       Impact factor: 12.984

6.  Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin.

Authors:  Robert Bucki; Jennifer J Pastore; Paramjeet Randhawa; Rolands Vegners; Daniel J Weiner; Paul A Janmey
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide.

Authors:  Huamei Fu; Lena Björkman; Paul Janmey; Anna Karlsson; Jennie Karlsson; Charlotta Movitz; Claes Dahlgren
Journal:  BMC Cell Biol       Date:  2004-12-29       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.